BioCentury
ARTICLE | Clinical News

IMCL reports encouraging data from three trials

May 14, 2001 7:00 AM UTC

IMCL reported data from three Phase II trials of its IMC-C225 monoclonal antibody against the EGF receptor (EGFr) to treat a variety of cancers, including refractory colorectal cancer, pancreatic cancer and refractory head and neck cancer. In a Phase II study of IMC-C225 in combination with irinotecan, 27 (23%) of 120 refractory colorectal cancer patients achieved a partial response(>50% tumor regression) and an additional 9 patients (8%) achieved stabilization of their disease. The median duration of response was 186 days.

In addition, IMCL said data from a 40-patient Phase II study of IMC-C225 in combination with gemcitabine to treat pancreatic cancer showed 5 patients (13%) achieved a partial response and an additional 21 patients (53%) achieved stabilization of disease. The median time to disease progression was about 3.5 months. The company also said the combination treatment produced a median overall survival of 6.75 months with a one-year overall survival rate of 32.5%. ...